NOTICE OF AN EXTRA GENERAL MEETING OF SHAREHOLDERS
Press Release, Stockholm, Sweden, February 25, 2008 – Diamyd Medical AB (www.omxgroup.com, ticker: DIAM B; www.otcqx.com, ticker DMYDY)
Diamyd Medical announced today a Notice of an Extra General Meeting of Shareholders on Monday March 10, 2008, at 3:00 PM, in the Company’s premises, Linnégatan 89B, Stockholm, Sweden.
Shareholders who wish to attend the Extra General Meeting must:
• be recorded in the Company’s register of shareholders, held by the VPC (the Swedish Securities Register Center) by March 4, 2008
• notify the Company of their intention to attend no later than 4:00 pm March 4, 2008 per phone: +46 8 661 0026 or per E-mail: investor.relations@diamyd.com. With the notification, name, address, phone number, social security number/national tax ID number, number of shares and name of agent should be stated.
Shareholders whose shares are registered in the name of a nominee through the trust department of a bank or similar institution must, in order to be entitled to participate in the Extra General Meeting, request that their shares are temporarily registered in their own names in the register of shareholders maintained by VPC. Such registration must be effective before March 4, 2008.
Agenda
1. Opening of the meeting
2. Election of the Chairman of the Extra General Meeting of Shareholders
3. Drawing up and approval of the voting list
4. Approval of the Agenda
5. Election of secretary and two persons to attest to the accuracy of the minutes
6. Decision on whether proper notice of the Extra General Meeting has been made
7. The Board of Directors proposal of Authorization
8. Closing the meeting
The Board of Directors proposal for Authorization (item 7)
The number of outstanding shares in the Company is 9,910,570 of which 561,671 of Series A (one vote) and 9,348,899 of Series B (1/10 vote). The number of votes amounts to 1,496,560.9 of which 561,671 are A-shares and 934,889.9 are B-shares.
The Board of Directors proposal for authorization on one or several occasions before the next Annual Shareholders’ Meeting, with or without consideration of the preferential shareholder rights to issue 91,000 shares of series B and warrants which will give the right to subscribe for 991,000 B-shares. The authorization is proposed to be valid for acquiring whole or parts of companies, assets, and cash or for settlements or other conditions as stated in chapter 2 §5 second paragraph 1-3 and 5 in the Companies Act. After full execution of the authorization of issuing shares in combination with the authorization given at the Annual Shareholders’ Meeting the dilution is calculated to 10 percent of the share capital, based on the total number of shares. After full execution of the authorization of the warrants and if they are fully subscribed, the dilution is calculated to additional 10 percent.
The full description of the proposal of the Board of Directors is available at the main office of Diamyd Medical: Linnégatan 89B, Stockholm, Sweden. At request this documentation can be sent for free to shareholders that state their full mailing address.